arrow
D

David Lillicrap

queens university - canada
H指数:66
被引数:1.5万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

A comprehensive care pathway of gene therapy for hemophilia based on current guideline documents and Summary of Product Characteristics (SMPCs); Communication from the ISTH SSC Working Group on Gene Therapy

基于现行指南文件和产品特性摘要(SmPCs)的血友病基因治疗综合护理路径;国际血栓与止血学会科学标准委员会基因治疗工作组通讯

2025-10-270
PRE
Large deletions in the F8 gene predict immune tolerance induction failure in people with severe hemophilia A

F8基因中的大片段缺失可预测严重血友病A患者免疫耐受诱导失败。

2025-10-100
OAAI
Regulation of immune responses to therapeutic factor VIII by transplacental delivery of Fc-fused immunodominant factor VIII domains or peptides

通过转胎传递Fc融合的免疫优势因子VIII结构域或肽来调节对治疗性因子VIII的免疫反应

2025-10-011
OAAI
Correction: A scan of pleiotropic immune mediated disease genes identifies novel determinants of baseline FVIII inhibitor status in hemophilia A

更正:对多效性免疫介导疾病基因的扫描识别出血友病A中基线FVIII抑制剂状态的新的决定因素

2025-09-250
PREAI
Effect of age on ISTH-BAT scores and Low VWF diagnosis in the Zimmerman Program.

年龄对ISTH-BAT评分和低VWF诊断在Zimmerman项目中的影响。

2025-07-030
OAAI
A scan of pleiotropic immune mediated disease genes identifies novel determinants of baseline FVIII inhibitor status in hemophilia A

对多效性免疫介导疾病基因的扫描识别出血友病A中基础FVIII抑制剂状态的新的决定因素

2025-04-220
PRE
Corticosteroid use to mitigate transaminitis-associated decline in FVIII levels following valoctocogene roxaparvovec gene therapy: clinical practice guidance

使用糖皮质激素以减轻valoctocogene roxaparvovec基因治疗后与转氨酶升高相关的FVIII水平下降:临床实践指南

2025-03-140
OAAI
Contrasting Approaches in the Implementation of GRADE Methodology in Guidelines for Haemophilia and Von Willebrand Disease
2024-12-090
PRE
International Society on Thrombosis and Haemostasis Clinical Practice Guideline for Treatment of Congenital Haemophilia-A Critical Appraisal
2024-12-060
PREAI
Prediction of the chance of successful immune tolerance induction in persons with severe hemophilia A and inhibitors: a clinical prediction model

预测严重血友病A和抑制剂患者成功诱导免疫耐受的机会: 临床预测模型

2024-10-010
OAAI
von Willebrand disease
2024-07-251
PRE